Living With Fibrosis Living With Fibrosis

Living With Fibrosis

We Are Here For Hope

Here at Pliant, the world’s top experts in fibrosis biology are hard at work with experienced drug developers to find safe and effective therapies for people with idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and other fibrotic diseases.

Bernard Coulie talks about Pliant’s commitment to working with the Pulmonary Fibrosis Foundation (PFF) and advancing therapies for people living with debilitating fibrotic diseases.

an oldmen looking far away

Clinical Trials for Idiopathic Pulmonary Fibrosis (IPF)

We have completed enrollment in our Phase 2a clinical trial of our lead investigational medicine, bexotegrast (PLN-74809).

Expanded Access Policy

Expanded Access, also known as “Compassionate Use” is a program that allows the individual patient use of an investigational medicinal product for an immediately life-threatening and serious disease or condition when enrollment in a clinical trial is not possible and no alternative therapy is available. This program only applies to medicines that have not yet been approved by the Food and Drug Administration (FDA). In considering a patient for Expanded Access, a doctor must decide whether the potential benefit outweighs the potential risk of receiving an investigational or unapproved medicine, based on the individual patient’s medical history. Because these drugs have yet to be approved, the full potential of their risks and benefits are not known.

The Pliant bexotegrast (PLN-74809) program is still in early-stage clinical development. As such, the benefit-risk assessments of PLN-74809 use are still being defined through ongoing clinical research and development. After careful consideration, Pliant Therapeutics does not feel there is enough information needed to assess whether the benefit outweighs the potential risk at this time. As a result, Pliant is not offering an Expanded Access to our investigational drug. We may consider offering this program as more information is revealed through progression of our investigational medicines through the various stages of clinical research and development.

For any further enquiries, Pliant can be reached at [email protected].

Clinical Trials for Primary Sclerosing Cholangitis (PSC)

We have completed enrollment of the INTEGRIS-PSC Phase 2a trial of our lead investigational medicine, bexotegrast (PLN-74809), in patients with primary sclerosing cholangitis (PSC).

Patient Resources


Enrollment Complete


Enrollment Complete

Clinical Trial FAQs


Find support and more information about fibrotic disease and how to participate in clinical trials from the following organizations.